Sei H. Yang
Iksan, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 17 publications
Korean Guidelines for the Diagnosis and Management of Interstitial Lung Disease: Other Forms of Interstitial Lung Disease.
Journal: Tuberculosis and respiratory diseases
Published: December 09, 2024
Real-world first-line afatinib for advanced EGFR mutation-positive non-small cell lung cancer in Korea: updated survival data.
Journal: Translational lung cancer research
Published: June 12, 2023
Role of ABCA2 and its single nucleotide polymorphisms (4873T>A and 4879G>C) in the regulation of multi-drug resistance in oral squamous carcinoma cells.
Journal: Biochemical and biophysical research communications
Published: April 21, 2023
Final Report on Real-World Effectiveness of Sequential Afatinib and Osimertinib in EGFR-Positive Advanced Non-Small Cell Lung Cancer: Updated Analysis of the RESET Study.
Journal: Cancer research and treatment
Published: March 22, 2023
Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors.
Journal: Translational lung cancer research
Published: November 24, 2022
TRPML3 enhances drug resistance in non-small cell lung cancer cells by promoting Ca2+-mediated lysosomal trafficking.
Journal: Biochemical and biophysical research communications
Published: August 08, 2022
Real-World Study of Osimertinib in Korean Patients with Epidermal Growth Factor Receptor T790M Mutation-Positive Non-Small Cell Lung Cancer.
Journal: Cancer research and treatment
Published: June 14, 2022
First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea.
Journal: Anticancer research
Published: December 28, 2021
Clinical Features, Diagnosis, Management, and Outcomes of Idiopathic Pulmonary Fibrosis in Korea: Analysis of the Korea IPF Cohort (KICO) Registry.
Journal: Tuberculosis and respiratory diseases
Published: August 08, 2021
Real-world experience of afatinib as first-line therapy for advanced EGFR mutation-positive non-small cell lung cancer in Korea.
Journal: Translational lung cancer research
Published: July 07, 2021
miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in Non-Small Cell Lung Cancer Cells by Targeting USP37.
Journal: Cancer research and treatment
Published: May 24, 2021
Sequential treatment of afatinib and osimertinib or other regimens in patients with advanced non-small-cell lung cancer harboring EGFR mutations: Results from a real-world study in South Korea.
Journal: Cancer medicine
Published: March 09, 2021
Last Updated: 09/26/2026